| TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment M Maddalena, G Mallel, NB Nataraj, M Shreberk-Shaked, O Hassin, ... Proceedings of the National Academy of Sciences 118 (23), e2025631118, 2021 | 73 | 2021 |
| The context-specific roles of urea cycle enzymes in tumorigenesis E Hajaj, M Sciacovelli, C Frezza, A Erez Molecular cell 81 (18), 3749-3759, 2021 | 44 | 2021 |
| Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study R Hadash-Bengad, E Hajaj, S Klein, S Merims, S Frank, G Eisenberg, ... Frontiers in oncology 10, 70, 2020 | 30 | 2020 |
| Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo G Eisenberg, R Engelstein, A Geiger-Maor, E Hajaj, S Merims, ... Cancer immunology research 6 (2), 127-138, 2018 | 26 | 2018 |
| SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint E Hajaj, G Eisenberg, S Klein, S Frankenburg, S Merims, I Ben David, ... Elife 9, e52539, 2020 | 23 | 2020 |
| 658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo)+ cis-vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC) MD Galsky, X Guan, R Banchereau, L Wang, J Zhu, H Yu, D Rishipathak, ... Annals of Oncology 32, S682-S683, 2021 | 15 | 2021 |
| Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions E Hajaj, E Zisman, S Tzaban, S Merims, J Cohen, S Klein, S Frankenburg, ... Cancer immunology research 9 (6), 637-650, 2021 | 10 | 2021 |
| Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis O Goldman, LN Adler, E Hajaj, T Croese, N Darzi, S Galai, H Tishler, ... Cancer discovery 13 (7), 1616-1635, 2023 | 7 | 2023 |
| Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer MD Galsky, X Guan, D Rishipathak, AS Rapaport, HM Shehata, ... Cell Reports Medicine 5 (2), 2024 | 2 | 2024 |
| From the Inside Out: Exposing the Roles of Urea Cycle Enzymes in Tumors and Their Micro and Macro Environments E Hajaj, S Pozzi, A Erez Cold Spring Harbor perspectives in medicine 14 (4), a041538, 2024 | | 2024 |
| Modulation of SLAMF6 splice variants for cancer therapy M Lotem, GM EISENBERG, E Hajaj US Patent 11,834,487, 2023 | | 2023 |
| The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma R Shreberk-Hassidim, A Geiger-Maor, G Eisenberg, S Merims, E Hajaj, ... Immunologic Research 70 (6), 793-799, 2022 | | 2022 |
| Combination cancer immunotherapy M Lotem, E Hajaj, G Eisenberg US Patent App. 17/622,225, 2022 | | 2022 |
| Nucleic acid agents modulating slamf6 isoforms M Lotem, E Hajaj, G Eisenberg US Patent App. 17/622,224, 2022 | | 2022 |
